Literature DB >> 34717009

Progressive decline of function in renal allografts with normal 1-year biopsies: Gene expression studies fail to identify a classifier.

Walter D Park1, Dean Y Kim2, Martin L Mai3, Kunam S Reddy4, Thomas Gonwa3, Margaret S Ryan4, Loren P Herrera Hernandez1, Maxwell L Smith4, Xochiquetzal J Geiger3, Sandor Turkevi-Nagy5, Lynn D Cornell1, Byron H Smith1, Walter K Kremers1, Mark D Stegall1.   

Abstract

Histologic findings on 1-year biopsies such as inflammation with fibrosis and transplant glomerulopathy predict renal allograft loss by 5 years. However, almost half of the patients with graft loss have a 1-year biopsy that is either normal or has only interstitial fibrosis. The goal of this study was to determine if there was a gene expression profile in these relatively normal 1-year biopsies that predicted subsequent decline in renal function. Using transcriptome microarrays we measured intragraft mRNA levels in a retrospective Discovery cohort (170 patients with a normal/minimal fibrosis 1-year biopsy, 54 with progressive decline in function/graft loss and 116 with stable function) and developed a nested 10-fold cross-validated gene classifier that predicted progressive decline in renal function (positive predictive value = 38 ± 34%%; negative predictive value = 73 ± 30%, c-statistic = .59). In a prospective, multicenter Validation cohort (270 patients with Normal/Interstitial Fibrosis [IF]), the classifier had a 20% positive predictive value, 85% negative predictive value and .58 c-statistic. Importantly, the majority of patients with graft loss in the prospective study had 1-year biopsies scored as Normal or IF. We conclude predicting graft loss in many renal allograft recipients (i.e., those with a relatively normal 1-year biopsy and eGFR > 40) remains difficult.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  genomics; glomerular filtration rate; kidney (allograft) function / dysfunction

Mesh:

Year:  2021        PMID: 34717009      PMCID: PMC8702476          DOI: 10.1111/ctr.14456

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  27 in total

1.  Identifying differentially expressed genes using false discovery rate controlling procedures.

Authors:  Anat Reiner; Daniel Yekutieli; Yoav Benjamini
Journal:  Bioinformatics       Date:  2003-02-12       Impact factor: 6.937

2.  Sparse inverse covariance estimation with the graphical lasso.

Authors:  Jerome Friedman; Trevor Hastie; Robert Tibshirani
Journal:  Biostatistics       Date:  2007-12-12       Impact factor: 5.899

3.  Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study.

Authors:  P F Halloran; J Reeve; E Akalin; O Aubert; G A Bohmig; D Brennan; J Bromberg; G Einecke; F Eskandary; C Gosset; J-P Duong Van Huyen; G Gupta; C Lefaucheur; A Malone; R B Mannon; D Seron; J Sellares; M Weir; A Loupy
Journal:  Am J Transplant       Date:  2017-05-30       Impact factor: 8.086

4.  Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials.

Authors:  Andrew Bentall; Byron H Smith; Manuel Moreno Gonzales; Keisha Bonner; Walter D Park; Lynn D Cornell; Patrick G Dean; Carrie A Schinstock; Richard Borrows; Carmen Lefaucheur; Alexandre Loupy; Mark D Stegall
Journal:  Am J Transplant       Date:  2019-03-13       Impact factor: 8.086

5.  Intragraft gene expression in positive crossmatch kidney allografts: ongoing inflammation mediates chronic antibody-mediated injury.

Authors:  P G Dean; W D Park; L D Cornell; J M Gloor; M D Stegall
Journal:  Am J Transplant       Date:  2012-02-15       Impact factor: 8.086

6.  Fibrosis with inflammation at one year predicts transplant functional decline.

Authors:  Walter D Park; Matthew D Griffin; Lynn D Cornell; Fernando G Cosio; Mark D Stegall
Journal:  J Am Soc Nephrol       Date:  2010-09-02       Impact factor: 10.121

7.  Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant.

Authors:  John J Friedewald; Sunil M Kurian; Raymond L Heilman; Thomas C Whisenant; Emilio D Poggio; Christopher Marsh; Prabhakar Baliga; Jonah Odim; Merideth M Brown; David N Ikle; Brian D Armstrong; Jane I Charette; Susan S Brietigam; Nedjema Sustento-Reodica; Lihui Zhao; Manoj Kandpal; Daniel R Salomon; Michael M Abecassis
Journal:  Am J Transplant       Date:  2018-08-31       Impact factor: 8.086

8.  Molecular evidence of injury and inflammation in normal and fibrotic renal allografts one year posttransplant.

Authors:  Walter Park; Matthew Griffin; Joseph P Grande; Fernando Cosio; Mark D Stegall
Journal:  Transplantation       Date:  2007-06-15       Impact factor: 4.939

9.  Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study.

Authors:  Alexandre Loupy; Olivier Aubert; Babak J Orandi; Maarten Naesens; Yassine Bouatou; Marc Raynaud; Gillian Divard; Annette M Jackson; Denis Viglietti; Magali Giral; Nassim Kamar; Olivier Thaunat; Emmanuel Morelon; Michel Delahousse; Dirk Kuypers; Alexandre Hertig; Eric Rondeau; Elodie Bailly; Farsad Eskandary; Georg Böhmig; Gaurav Gupta; Denis Glotz; Christophe Legendre; Robert A Montgomery; Mark D Stegall; Jean-Philippe Empana; Xavier Jouven; Dorry L Segev; Carmen Lefaucheur
Journal:  BMJ       Date:  2019-09-17

10.  The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

Authors:  M Haas; A Loupy; C Lefaucheur; C Roufosse; D Glotz; D Seron; B J Nankivell; P F Halloran; R B Colvin; Enver Akalin; N Alachkar; S Bagnasco; Y Bouatou; J U Becker; L D Cornell; J P Duong van Huyen; I W Gibson; Edward S Kraus; R B Mannon; M Naesens; V Nickeleit; P Nickerson; D L Segev; H K Singh; M Stegall; P Randhawa; L Racusen; K Solez; M Mengel
Journal:  Am J Transplant       Date:  2018-01-21       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.